A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer

Journal of Neuro-Oncology

Volumn 113, Issue 1, 2013, Pages 83-92

  Le Rhun, E ^b   Taillibert, S ^c   Zairi, F ^b   Kotecki, N ^d   Devos, P ^b,e   Mailliez, A ^d   Servent, V ^d   Vanlemmens, L ^d   Vennin, P ^d   Boulanger, T ^d   Baranzelli, M C ^d   Andre C ^d   Marliot, G ^d   Cazin, J L ^d,e   Dubois, F ^b   Assaker, R ^b,e   Bonneterre, J ^c,e   Chamberlain, M C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e UNIV LILLE   (France)

Author keywords

Breast cancer; Intra CSF treatment; Leptomeningeal metastasis; Liposomal cytarabine

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; THIOTEPA;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CEREBROSPINAL FLUID CYTOLOGY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; INTRACRANIAL HYPERTENSION; LEPTOMENINGEAL METASTASIS; LIVER METASTASIS; LUNG METASTASIS; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MENINGEAL METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INJECTIONS, SPINAL; KAPLAN-MEIER ESTIMATE; LIPOSOMES; MENINGEAL CARCINOMATOSIS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84876936269     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1092-8     Document Type: Article

References (50)

1. Kesari S, Batchelor TT (2003) Leptomeningeal metastases. Neurol Clin 21:25-66
2. Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM (2010) Leptomeningeal metastases in the MRI era. Neurology 74(18):1449-1454
3. Chamberlain MC, Glantz M, Groves MD, Wilson WH (2009) Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol 36(4 Suppl 2):S35-S45
4. Groves MD (2010) New strategies in the management of leptomeningeal metastases. Arch Neurol 67(3):305-312
5. Rudnicka H, Niwinska A, Murawska M (2007) Breast cancer leptomeningeal metastasis - the role of multimodality treatment. J Neurooncol 84:57-62
6. Clatot F, Philippin-Lauridant G, Ouvrier MJ, Nakry T, Laberge-Le-Couteulx S, Guillemet C, Veyret C, Blot E (2009) Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy. J Neurooncol 95(3):421-426
7. Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, Laurence V, Livartowski A, Mignot L, Diéras V (2010) Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol 21(11):2183-2187
8. de Azevedo CR, Cruz MR, Chinen LT, Peres SV, Peterlevitz MA, de Azevedo Pereira AE, Fanelli MF, Gimenes DL (2011) Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J Neurooncol 104(2):565-572
9. Lee S, Ahn HK, Park YH, Nam do H, Lee JI, Park W, Choi DH, Huh SJ, Park KT, Ahn JS, Im YH (2011) Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat 129(3):809-817
10. Chamberlain MC (2006) Neoplastic meningitis. Neurologist 12(4):179-187
11. Lamovec J, Bracko M (1991) Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol 48:28-33
12. Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, Rivera E (2007) Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 110(12):2640-2647
13. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113(10):2638-2645
14. Le Rhun E, Taillibert S, Zairi F, Devos P, Pierret MF, Dubois F, Assaker R, Buisset E, Bonneterre J, Baranzelli MC (2011) Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: a case-control study. J Neurooncol 105(2):309-315
15. Rakha EA, El-Sayed M, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25-32
16. Lin NU (2010) Concordance of HER2 in primary tumor and leptomeningeal metastases: now what? Breast Cancer Res Treat 123(1):129-131
17. Glass JP, Melamed M, Chernik NL, Posner JB (1979) Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29:1369-1375
18. Wasserstrom WR, Glass JP, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49:759-772
19. Chamberlain MC (2010) Leptomeningeal metastasis. Curr Opin Oncol 22(6):627-635
20. Chamberlain MC (2012) Neuraxis imaging in leptomeningeal metastasis: a retrospective case series. General poster session, Abstract 2046 American Society of Clinical Oncology, Annual Meeting, 2012, June, Chicago, IL, J Clin Oncol, 30
21. Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM (2012) Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 7(2):382-385
22. Park JH, Kim YJ, Lee JO, Lee KW, Kim JH, Bang SM, Chung JH, Kim JS, Lee JS (2012) Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 76(3):387-392
23. Bleyer WA, Drake J, Chabner B (1973) Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. N Engl J Med 289:770-773
24. Bleyer WA, Poplack DG, Simon RM (1978) "Concentration time" methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 51:835-842
25. Taillibert S, Laigle-Donadey F, Chodkiewicz C, Sanson M, Hoang-Xuan K, Delattre JY (2005) Leptomeningeal metastases from solid malignancy: a review. J Neurooncol 75(1):85-99
26. Poplack D, Bleyer WA, Horowitz M (1980) Pharmacology of antineoplastic agents in cerebrospinal fluid.In: Wood J (ed) Neurology of cerebrospinal fluid. Plenum Press, New York, p 561-578
27. Grewal J, Saria MG, Kesari S (2012) Novel approaches to treating leptomeningeal metastases. J Neurooncol 106(2):225-234
28. Shapiro WR, Young DF, Mehta BM (1975) Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293:161-166
29. Boogerd W, Hart AA, van der Sande JJ, Engelsman E (1991) Meningeal carcinomatosis in breast cancer. Cancer 15:1685-1695
30. Glantz MJ, LaFollette S, Jaeckle K (1999) Randomized trial of a slow- release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110-3116
31. Glantz MJ, Van Horn A, Fisher R, Chamberlain MC (2010) Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer 116:1947-1952
32. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Mounihan T, Ettinger DS (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11:561-569
33. Hitchins RN, Bell DR, Woods RL, Levi JA (1987) A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5:1655-1662
34. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF, Howell SB (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:3394-3402
35. Cole BF, Glantz MJ, Jaeckle KA, Chamberlain MC, Mackowiak JI (2003) Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 97:3053-3060
36. Chamberlain MC, Khatibi S, Kim JC, Howell SB, Chatelut E, Kim S (1993) Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch Neurol 50:261-264
37. Boogerd W, van der Sande JJ, Moffie D (1988) Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry 51(10):1277-1283
38. Gutierrez M, Fourme E, Taillibert S, Le Rhun E, Tredan O, Gunzer K, Diéras V, Mefti F, Vago-Ady N, Tresca P, Turbiez I, Paintaud G, Brain E (2012) HIT: a multicenter phase I-II study of trastuzumab administered by intrathecal injection for leptomeningeal meningitis of HER2. Metastatic breast cancer. General poster session, abstract TPS662, American Society of Clinical Oncology, Annual Meeting, 2012, June, Chicago, IL, J Clin Oncol, 30
39. Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, Ro J (2008) Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 10(1):R20
40. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97(12):2972-2977
41. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O'Day SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russel C, Shapiro W, Swinnen L, Howell SB (2001) Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 84:157-163
42. Chamberlain MC, Kormanik PA (1997) Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol 54:1364-1368
43. Chamberlain M (1998) Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol 37:271-284
44. Harstad L, Hess KR, Groves MD (2008) Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. J Neurooncol 10:1010-1018
45. Herrlinger U, Fösrschier H, Küker W, Meyermann R, Bamberg M, Dichgns J, Weller M (2004) Leptomeningeal metastasis: survival and prognosis in 155 patients. J Neurol Sci 223(2):167-178
46. Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit M (2010) Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol 136(11):1729-1735
47. Brem SS, Bierman PJ, Black P, Blumenthal DT, Brem H, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Fine HA, Friedman A, Glass J, Grossman SA, Heimberger AB, Junck L, Levin V, Loeffler JJ, Maor MH, Narayana A, Newton HB, Olivi A, Portnow J, Prados M, Raizer JJ, Rosenfeld SS, Shrieve DC, Jr Stills AK, Spence AM, Vrionis FD (2005) National Comprehensive Cancer Network, Central nervous system cancers: clinical practice guidelines in oncology. J Natl Compr Canc Netw 3:644-690
48. Chamberlain MC, Kormanik PA (1996) Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 46:1674-1677
49. Chamberlain MC (2004) Neoplastic meningitis: deciding who to treat. Exp Rev Neurother 4:89-96
50. Chamberlain MC, Tsao-Wei D, Groshen S (2004) Neoplastic meningitis-related encephalopathy: prognostic significance. Neurology 63:2159-2161